A Randomized Controlled Study on the Effectiveness, Safety and Adaptability of Double Helix Design Defocus Lens Spectacle Frames for Correction of Visual Acuity in Children and Adolescents, and Control of Myopia.

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study uses 1.585 double helix defocus lens PC lenses with a unique optical design that includes a globally coherent visible area and complementary left and right helices that can form clear images. In addition, the helical arrangement and reduced slit area can generate defocusing signals, inhibiting the development of myopia. Therefore, based on previous research, this study plans to evaluate the safety and effectiveness of 1.585 double helix defocus lens PC frame eyeglasses in controlling the progression of myopia in children and adolescents through a randomized controlled clinical trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 13
Healthy Volunteers: f
View:

⁃ Race: Chinese children and adolescents.

⁃ Age 6-13 years, gender unrestricted.

⁃ Cycloplegic refraction SER: -0.75DS\

• 5.0DS in both eyes.

⁃ Best corrected visual acuity of both eyes reaches 1.0 (0.00 logMAR 6/6).

⁃ Refractive astigmatism and astigmatism are no more than 1.5D.

⁃ During the study period, willing to wear glasses provided by the researcher only (\>10 hours) and without additional interventions.

⁃ Willing to be randomly assigned.

⁃ Able to sign an informed consent form with the accompaniment and understanding of parents or guardians.

Locations
Other Locations
China
Xiangui He
RECRUITING
Shanghai
Time Frame
Start Date: 2023-06-03
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 264
Treatments
Experimental: Group A
Double Helix Design Defocus Lens Spectacle (RACE) for 2 years
Placebo_comparator: Group B
1. st year: single-vision spectacle lenses~2. nd year: double helix design defocus lens spectacle (RACE)
Related Therapeutic Areas
Sponsors
Leads: Shanghai Eye Disease Prevention and Treatment Center

This content was sourced from clinicaltrials.gov